Text size <\/p>\n
The biggest healthcare industry conference of the year opened Monday with a wave of announcements and partnerships, but no blockbuster biotech acquisitions.<\/p>\n
That could be a disappointment to investors, who had been hoping for a busy 2022 for biotech M&A. The sector performed miserably last year and into early January.<\/p>\n
The first morning of the J.P. Morgan Healthcare Conference is often a stage for big pharmaceutical companies to unveil major deals. On the first day of 2019s conference, for example, Eli Lilly (ticker: LLY) announced the $8 billion acquisition of Loxo Oncology.<\/p>\n
Nothing like that has happened yet on Monday morning. With the Biotech sell off accelerating in the first week of January, the lack of any M&A at JPM is unwelcome news for anyone long the space, Jefferies healthcare equity strategist Will Sevush wrote in a note to investors early Monday.<\/p>\n
While investors hoping for a big biotech acquisition may be disappointed, there has been plenty of healthcare news announced to coincide with the start of the conference. Here are some highlights so far.<\/p>\n
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com<\/a><\/p>\n <\/p>\n Go here to read the rest: <\/p>\n J.P. Morgan Healthcare Conference Starts With Lots of Deals, No Blockbuster M&A - Barron's<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Text size The biggest healthcare industry conference of the year opened Monday with a wave of announcements and partnerships, but no blockbuster biotech acquisitions. That could be a disappointment to investors, who had been hoping for a busy 2022 for biotech M&A. The sector performed miserably last year and into early January. Continue reading